Cathlin M Flamme

Publications (2)7.9 Total impact

• Article: The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

  Stephen D Barrett, Alexander J Bridges, David T Dudley, Alan R Saltiel, James H Fergus, Cathlin M Flamme, Amy M Delaney, Michael Kaufman, Sophie LePage, Wilbur R Leopold, Sally A Przybranowski, Judith Sebolt-Leopold, Keri Van Becelaere, Annette M Doherty, Robert M Kennedy, Dan Marston, W Allen Howard, Yvonne Smith, Joseph S Warmus, Haile Tecle
  [show abstract] [hide abstract]
  ABSTRACT: A novel series of benzhydroxamate esters derived from their precursor anthranilic acids have been prepared and have been identified as potent MEK inhibitors. 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopropylmethoxy-3,4-difluoro-benzamide, CI-1040, was the first MEK inhibitor to demonstrate in vivo activity in preclinical animal models and subsequently became the first MEK inhibitor to enter clinical trial. CI-1040 suffered however from poor exposure due to its poor solubility and rapid clearance, and as a result, development of the compound was terminated. Optimization of the diphenylamine core and modification of the hydroxamate side chain for cell potency, solubility, and exposure with oral delivery resulted in the discovery of the clinical candidate N-(2,3-dihydroxy-propoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide PD 0325901.
  Bioorganic & medicinal chemistry letters 11/2008; 18(24):6501-4. · 2.65 Impact Factor
• Article: 4-anilino-5-carboxamido-2-pyridone derivatives as noncompetitive inhibitors of mitogen-activated protein kinase kinase.

  Julie A Spicer, Gordon W Rewcastle, Michael D Kaufman, Shannon L Black, Mark S Plummer, William A Denny, John Quin, Aurash B Shahripour, Stephen D Barrett, Christopher E Whitehead, [......], Nadia Esmaeil, Kelley Moore, Judith S Sebolt-Leopold, Sally Pryzbranowski, Ronald L Merriman, Daniel F Ortwine, Joseph S Warmus, Cathlin M Flamme, Alexander G Pavlovsky, Haile Tecle
  [show abstract] [hide abstract]
  ABSTRACT: A new series of MEK1 inhibitors, the 4-anilino-5-carboxamido-2-pyridones, were designed and synthesized using a combination of medicinal chemistry, computational chemistry, and structural elucidation. The effect of variation in the carboxamide side chain, substitution on the pyridone nitrogen, and replacement of the 4'-iodide were all investigated. This study afforded several compounds which were either equipotent or more potent than the clinical candidate CI-1040 (1) in an isolated enzyme assay, as well as murine colon carcinoma (C26) cells, as measured by suppression of phosphorylated ERK substrate. Most notably, pyridone 27 was found to be more potent than 1 in vitro and produced a 100% response rate at a lower dose than 1, when tested for in vivo efficacy in animals bearing C26 tumors.
  Journal of Medicinal Chemistry 11/2007; 50(21):5090-102. · 5.25 Impact Factor